LiveNova Logo

TandemLife is now a part of LivaNova, Learn More Here.

COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.



855 336 3051 REIMBURSEMENT

800 373 1607 US

412 507 6182 INTERNATIONAL




The United States Food and Drug Administration, on Monday, April 6, 2020, issued a guidance document to expand the availability of devices used for extracorporeal membrane oxygenation (ECMO) therapy to address the Coronavirus Disease 2019 (COVID-19) Pandemic. This policy is intended to remain in effect only for the duration of the public health emergency related

In his own words, Robert Barton describes his experience on TandemHeart support


Check out Robert Burton’s story of survival and journey to a kidney transplant.  Click HERE.

Dr. Christopher Overgaard (Peter Munk Cardiac Centre – UHN) discusses his recent use of the TandemHeart Device


In his own words – TandemHeart – Dr. Christoper Overgaard *Device duration varies by country. Indications for Use – USA TandemHeart Pump: The TandemHeart System is intended for extracorporeal circulatory support using an extracorporeal bypass circuit. Intended duration of use is for periods appropriate to cardiopulmonary bypass, up to six hours. It is also intended

First-in-Canada successful implant of cardiac-assist device in high-risk heart patient


-Courtesy of Peter Munk Cardiac Centre UHN- TandemHeart System offers new option to treat clinically-challenging cardiac condition A multi-disciplinary medical team of interventional and structural cardiologists at the Peter Munk Cardiac Centre, University Health Network, has successfully completed a Canadian first — the implant of a TandemHeart circulatory support device designed to take over the

The Next Era of CPR


Our company is working to simplify life support by focusing on ease of use for clinicians and accessibility for patients.  Our new TandemLife kit  will be packaged in a small, sterile basin so that emergent CBP can be initiated quickly in a variety of environments.  Click the link to learn how TandemLife is contributing to

ECLS Products among the Most Exciting Cardiac Care Developments


In a recent interview  Zain Khalpey, M.D (Director, Artificial Heart & ECMO Program, Banner University), describes the method of treating emergent cardiac failure situations with ECLS prior to full Left Ventricular unloading as the paradigm shift need to help improve results. Click the following link for the full interview:   _ _ _ _

Heart transplant recipient receives the world’s first 31 Fr ProtekDuo™ cannula in a life-saving TandemLung® case


TandemLife® reveals details of the first clinical use of their new 31 Fr ProtekDuo cannula in combination with the recently released TandemLung oxygenator We’re thrilled to announce the commercial launch and first human use of our newest ProtekDuo dual lumen cannula at Cedars Sinai Heart Institute in Los Angeles. The cardiothoracic transplant team said the

TandemLife Named as Finalist for Pittsburgh Technology Council’s Tech 50 Innovator of the Year Award


TandemLife announced today, August 18th, that the Pittsburgh Technology Council has named it a Tech 50 Awards Finalist for the Innovator of the Year: Life Sciences category. “We are honored to have earned a place among some of the best life sciences companies in our region as one of the Tech50 finalists,” said John Marous,